Opendata, web and dolomites

Delirium Monitor

Objective delirium detection with an innovative EEG-based spot monitor

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Delirium Monitor project word cloud

Explore the words cloud of the Delirium Monitor project. It provides you a very rough idea of what is the project "Delirium Monitor" about.

medical    cognitive    70    minute    reported    diabetes    clinical    first    validation    frightening    commercialize    outcome    delirium    electrode    undertreated    ce    acute    budget    unmet    million    nl    despite    nursing    care    billion    granted    home    decades    market    incidences    134    total    thereafter    patients    grows    certification    umc    society    usa    intensive    hospital    months    stay    costly    commit    stresses    impaired    electrodes    noise    sme    detect    double    serious    2021    automated    mm    aging    prolonged    sometimes    discharge    healthcare    patch    80    dementia    disposable    functioning    start    impairs    brain    sales    mount    create    patent    times    equaling    customers    millions    generates    yearly    biomarker    risk    device    feasibility    day    showed    decline    hospitalized    horrifying    icu    detection    revenue    specialized    elderly    monitored    world    license    employees    2016    burden    fatal    utrecht    2017    40    engineering    hallucinations    surgical    rate    length    frequency    underdiagnosed    recording    eeg    alone   

Project "Delirium Monitor" data sheet

The following table provides information about the project.

Coordinator
WILLEMS-TJOE NIJ ANNEMARIE CHRISTINE 

Organization address
address: FRED PETTERBAAN 21
city: AMSTERDAM
postcode: 1019 JT
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.prolira.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WILLEMS-TJOE NIJ ANNEMARIE CHRISTINE NL (AMSTERDAM) coordinator 50˙000.00

Map

 Project objective

Delirium –an acute decline in cognitive functioning– is common, serious, frightening, costly and sometimes fatal. Delirium is a great burden for patients because of horrifying hallucinations and impaired outcome and increased risk on dementia. Delirium stresses society because of increased healthcare costs. This is due to prolonged length of hospital stay, and increased rate of discharge to a nursing home thereafter. Costs due to delirium total to €134 billion/year in Europe alone, equaling costs associated with diabetes. Delirium particularly affects hospitalized elderly with reported incidences of 50-80% on the Intensive Care Unit (ICU), and 10-40% in surgical patients. Because of our aging society, patients at risk for delirium will double in the next decades. Despite its frequency and impact, delirium remains underdiagnosed and therefore undertreated. Delirium is not recognized in 50 - 70% of the cases, which impairs outcome. Early and objective detection of delirium is an unmet clinical need. Mount Medical (MM), an SME specialized in medical devices, will create and commercialize the world’s first biomarker based device to detect delirium. UMC Utrecht (NL) showed that 1 minute recording of brain activity (EEG) with only 3 electrodes and automated processing could very well identify patients with delirium. A license on the patent will be granted to MM. Yearly, millions of patients are at risk of delirium that need to be monitored 3 times per day. This generates a €1.4 billion market in the EU and the USA, as for every measurement, a disposable electrode patch is necessary. A 6 months Phase 1 budget enables biomarker validation and development of noise reduction technology to show technical feasibility, and to commit customers into an Early Access program for market feasibility. Phase 2 is for product engineering and CE certification. EU sales start in 2016, and USA sales in 2017. MM grows to €10 million in revenue and 50 employees in 2021.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DELIRIUM MONITOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DELIRIUM MONITOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

FURTHER (2019)

Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone Metastasis

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

SMA-TB (2020)

A novel Stratified Medicine Algorithm to predict treatment responses to host-directed therapy in TB patients.

Read More